CD147 immunohistochemistry discriminates between reactive mesothelial cells and malignant mesothelioma

Diagnostic Cytopathology

Volumn 40, Issue 6, 2012, Pages 478-483

  Pinheiro, Céline ^a,b   Longatto Filho, Adhemar ^a,b,c   Soares, Tony R ^a,b   Pereira, Helena ^b   Bedrossian, Carlos ^d   Michael, Claire ^e   Schmitt, Fernando C ^f,g   Baltazar, Fátima ^a,b  

^a UNIVERSITY OF MINHO   (Portugal)

^b UNIVERSITY OF MINHO   (Portugal)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d RUSH MEDICAL COLLEGE   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f University of Porto   (Portugal)

^g UNIVERSITY OF PORTO   (Portugal)

Author keywords

CD147 EMMPRIN; lactate; malignant mesothelioma; monocarboxylate transporters

Indexed keywords

CD147 ANTIGEN; GLUCOSE TRANSPORTER 1; MONOCARBOXYLATE TRANSPORTER 1; MONOCARBOXYLATE TRANSPORTER 4;

ADULT; AGED; CLINICAL ARTICLE; CONFERENCE PAPER; FEMALE; HUMAN; HUMAN CELL; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MALE; MALIGNANT MESOTHELIOMA; MESOTHELIUM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; AGED, 80 AND OVER; ANTIGENS, CD147; CELL MEMBRANE; CELL PROLIFERATION; CYTOPLASM; FEMALE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MONOCARBOXYLIC ACID TRANSPORTERS; MUSCLE PROTEINS; NEOPLASMS, MESOTHELIAL; SYMPORTERS; TUMOR MARKERS, BIOLOGICAL;

EID: 84861540266     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.22821     Document Type: Conference Paper

References (33)

1. Bedrossian CWM,. Asbestos-related diseases-A historical and mineralogic perspective-Introduction. Semin Diagn Pathol 1992; 9: 91-96.
2. Grondin SC, Sugarbaker DJ,. Malignant mesothelioma of the pleural space. Oncology (New York) 1999; 13: 919-926.
3. Sugarbaker DJ, Wolf AS,. Surgery for malignant pleural mesothelioma. Expert Rev Respir Med 2010; 4: 363-372.
4. Ray M, Kindler HL,. Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest 2009; 136: 888-896.
5. Bertino P, Carbone M, Pass H,. Chemotherapy of malignant pleural mesothelioma. Expert Opin Pharmacother 2009; 10: 99-107.
6. van der Most RG, Robinson BWS, Nelson DJ,. Gene therapy for malignant mesothelioma: Beyond the infant years. Cancer Gene Ther 2006; 13: 897-904.
7. Nowak AK, Lake RA, Kindler HL, Robinson BWS,. New approaches for mesothelioma: Biologics, vaccines, gene therapy, and other novel agents. Semin Oncol 2002; 29: 82-96.
8. Pasello G, Favaretto A,. Molecular targets in malignant pleural mesothelioma treatment. Curr Drug Targets 2009; 10: 1235-1244.
9. Bedrossian CWM,. Diagnostic problems in serous effusions. Diagn Cytopathol 1998; 19: 131-137.
10. Bedrossian CWM,. Special stains, the old and the new: The impact of immunocytochemistry in effusion cytology. Diagn Cytopathol 1998; 18: 141-149.
11. Lyons-Boudreaux V, Mody DR, Zhai J, Coffey D,. Cytologic malignancy versus benignancy-How useful are the "Newer" markers in body fluid cytology? Arch Pathol Lab Med 2008; 132: 23-28.
12. Hasteh F, Lin GY, Weidner N, Michael CW,. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions. Cancer Cytopathol 2010; 118: 90-96.
13. Kato Y, Tsuta K, Seki K, Maeshima AM,. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol 2007; 20: 215-220.
14. Shen J, Pinkus GS, Deshpande V, Cibas ES,. Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids. Am J Clin Pathol 2009; 131: 516-523.
15. Bury T, Paulus P, Dowlati A, Corhay JL, Rigo P, Radermecker MF,. Evaluation of pleural diseases with FDG-PET imaging: Preliminary report. Thorax 1997; 52: 187-189.
16. Carretta A, Landoni C, Melloni G,. 18-FDG positron emission tomography in the evaluation of malignant pleural diseases-A pilot study. Eur J Cardiothorac Surg 2000; 17: 377-383.
17. Benard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A,. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest 1998; 114: 713-722.
18. Davidson B, Vintman L, Zcharia E, Bedrossian C, Berner A, Nielsen S, Ilan N, Vlodavsky I, Reich R,. Heparanase and basic fibroblast growth factor are co-expressed in malignant mesothelioma. Clin Exp Metastasis 2004; 21: 469-476.
19. Brizel DM, Schroeder T, Scher RL,. Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001; 51: 349-353.
20. Quennet V, Yaromina A, Zips D,. Tumor lactate content predicts for response to fractionated irradiation of human squamous cell carcinomas in nude mice. Radiother Oncol 2006; 81: 130-135.
21. Walenta S, Wetterling M, Lehrke M,. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res 2000; 60: 916-921.
22. Pinheiro C, Longatto-Filho A, Ferreira L,. Increasing expression of monocarboxylate transporters 1 and 4 along progression to invasive cervical carcinoma. Int J Gynecol Pathol 2008; 27: 568-574.
23. Pinheiro C, Longatto A, Pereira SMM,. Monocarboxylate transporters 1 and 4 are associated with CD147 in cervical carcinoma. Dis Markers 2009; 26: 97-103.
24. Pinheiro C, Longatto-Filho A, Scapulatempo C,. Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. Virchows Arch 2008; 452: 139-146.
25. Pinheiro C, Albergaria A, Paredes J,. Monocarboxylate transporter 1 is up-regulated in basal-like breast carcinoma. Histopathology 2010; 56: 860-867.
26. Pinheiro C, Longatto-Filho A, Simoes K,. The prognostic value of CD147/EMMPRIN is associated with monocarboxylate transporter 1 co-expression in gastric cancer. Eur J Cancer 2009; 45: 2418-2424.
27. Kennedy KM, Dewhirst MW,. Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation. Future Oncol 2010; 6: 127-148.
28. Scurry J, Duggan MA,. Malignant mesothelioma eight years after a diagnosis of atypical mesothelial hyperplasia. J Clin Pathol 1999; 52: 535-537.
29. Bougatef F, Quemener C, Kellouche S,. EMMPRIN promotes angiogenesis through hypoxia-inducible factor-2alpha-mediated regulation of soluble VEGF isoforms and their receptor VEGFR-2. Blood 2009; 114: 5547-5556.
30. Filho AL, Baltazar F, Bedrossian C, Michael C, Schmitt FC,. Immunohistochemical expression and distribution of VEGFR-3 in malignant mesothelioma. Diagn Cytopathol 2007; 35: 786-791.
31. Lumb PD, Suvarna SK,. Metastasis in pleural mesothelioma. Immunohistochemical markers for disseminated disease. Histopathology 2004; 44: 345-352.
32. Ceresoli GL, Chiti A, Zucali PA,. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [F-18] fluorodeoxyglucose. J Clin Oncol 2006; 24: 4587-4593.
33. Yan TD, Deraco M, Baratti D,. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 2009; 27: 6237-6242.